Processing autologuous peripheral blood progenitor cell (PBPC) products to obtain a CD 34+ cell enriched population intended for hematopoietic reconstitution after myeloablative therapy in patients with CD 34-negative tumors.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2t6jWKi
No comments:
Post a Comment